---
layout: topic-review
title: "Pancreas"
redirect_from:
  - /absite/11_09-pancreas/
permalink: /landmark/topic-review/pancreas/
---

# Pancreas Review

Use the collapsible section below. The floating Table of Contents on the right lists all major headings (≤20) for quick navigation.

<!-- Compact, mobile-friendly table styling (works with Markdown tables) -->
<style>
.qr-table { width:100%; }
.qr-table th, .qr-table td { padding:.4rem .5rem; border-top:1px solid #e5e7eb; vertical-align:top; }
.qr-note { margin:.25rem 0 .5rem; font-weight:600; }
</style>

---

<details markdown="1" open>
<summary><strong>Pancreas</strong></summary>

<br>

### Anatomy & Physiology
- **Parts:** head (incl. uncinate), neck, body, tail. **Uncinate** rests on aorta, behind SMV. **PV** forms behind neck (SMV + splenic v.).  
- **Arterial supply:** **head**—superior (off GDA) & inferior (off SMA) pancreaticoduodenal a.’s; **body/tail**—great, inferior, dorsal pancreatic a.’s (off splenic).  
- **Venous drainage:** into portal system. **Lymphatics:** celiac & SMA nodes.  
- **Ductal cells** secrete **HCO₃⁻**; **acinar cells** secrete digestive enzymes (amylase, lipase, trypsinogen, chymotrypsinogen, carboxypeptidase).  
- **Exocrine pearls:** **amylase** only pancreatic enzyme secreted in **active** form; trypsin activates other zymogens.  
- **Endocrine islet cells:** α (glucagon), β (insulin), δ (somatostatin), PP cells (pancreatic polypeptide).  
- **Blood flow sequence:** islets → acini (“islet–acinar portal system”).  
- **Hormonal control:** secretin ↑ HCO₃⁻; **CCK** ↑ enzymes; ACh ↑ both; **somatostatin & glucagon** ↓ exocrine function.  
- **Sphincter of Oddi:** **CCK & glucagon relax**; morphine contracts.

### Congenital & Structural Variants
- **Annular pancreas:** duodenal obstruction (double-bubble). Assoc. with Down syndrome. **Tx:** duodenojejunostomy or duodenoduodenostomy (± sphincteroplasty). Pancreas **not** resected.  
- **Pancreas divisum:** failed duct fusion; minor papilla drains majority; can cause pancreatitis from accessory duct stenosis. **Dx:** ERCP—long minor duct; **Tx:** ERCP with minor papilla sphincteroplasty ± stent; open sphincteroplasty if endoscopic fails.  
- **Heterotopic pancreas:** often duodenum; usually incidental; resect if symptomatic.

### Acute Pancreatitis
- **Common causes:** gallstones, alcohol (others: hyperTG, hyperCa, ERCP, meds, trauma, scorpion, autoimmune, genetic).  
- **Dx:** 2 of 3—typical pain; lipase ≥3× ULN; imaging findings.  
- **Initial care:** aggressive IV fluids (first 24 h), analgesia, early **enteral** nutrition. Avoid TPN unless necessary.  
- **Gallstone pancreatitis:** **clear duct if cholangitis/obstruction** (ERCP). Perform **cholecystectomy same admission** when clinically improved.  
- **Abx:** **not indicated** for uncomplicated pancreatitis or **sterile** necrosis. Use for **infected** necrosis (fever, leukocytosis, sepsis, gas on CT, positive cultures). **Imipenem** commonly used.  
- **Imaging:** CT for complications (necrosis, collections). US to assess stones/CBD.

**Ranson Criteria (Non-Gallstone; initial & 48 h)**  
{:.qr-note}

| Time | Criterion |
|---|---|
| **Admission** | Age >55; WBC >16; Glucose >200; AST >250; LDH >350 |
| **At 48 h** | Hct ↓ >10%; BUN ↑ >5; Ca <8; PaO₂ <60; Base deficit >4; Fluid sequestration >6 L |
{:.qr-table}

*Interpretation:* more criteria → higher mortality; use for trend/comparison (not sole management driver).

**Revised Atlanta – Post-Pancreatitis Fluid Collections**  
{:.qr-note}

| <4 weeks | ≥4 weeks | Contents | Wall | Typical term | Notes |
|---|---|---|---|---|---|
| Acute **peri-pancreatic fluid collection** | **Pseudocyst** | Fluid only | None → Mature | Pseudocyst | Many resolve; treat if symptomatic, infected, or >6 cm persisting |
| **Acute necrotic collection** | **Walled-off necrosis (WON)** | Fluid **+** necrosis | None → Mature | WON | Intervene if infected or symptomatic |
{:.qr-table}

### Necrotizing Pancreatitis & Step-Up
- **Infected necrosis** suspected with sepsis, persistent organ failure, **gas in collection**, or positive culture (FNA rarely required if obvious).  
- **Preferred strategy:** **delay** until demarcation → **percutaneous or endoscopic drainage** → **VARD/endoscopic necrosectomy** if needed → **open** necrosectomy only if failure/instability.  
- **Nutrition:** enteral (post-pyloric if needed).

**Infected Necrosis – Step-Up Pathway**  
{:.qr-note}

| Clinical state | First step | If inadequate | Last resort | Rationale |
|---|---|---|---|---|
| Stable, suspected infection | Broad-spectrum abx; **percutaneous or EUS-guided drainage** | **VARD** / endoscopic necrosectomy | **Open** necrosectomy | Staged source control lowers morbidity/mortality |
{:.qr-table}

### Pancreatic Pseudocyst
- More common with **chronic** pancreatitis; can follow acute.  
- **Observe ≥6 weeks** (many resolve; wall maturation).  
- **Indications for intervention:** symptoms (pain, infection, bleeding, obstruction), size **>6 cm** persisting, rapid growth.  
- **Image duct first** (ERCP or MRCP).  
- **Approaches:** endoscopic transpapillary stenting (if duct communication), **EUS-guided transmural drainage (cystgastro/duodenostomy)**, or surgical (lap/open) cystgastrostomy.

### Pancreatic Fistulas & Pancreatic Pleural Effusion
- **Postop fistulas:** most close spontaneously (esp. <200 cc/d). **Tx:** drain, NPO, TPN if needed, **octreotide**. If persistent → ERCP with sphincterotomy ± **pancreatic stent**; remove stent after closure.  
- **Pancreatic pleural effusion/ascites:** retroperitoneal leak from duct or pseudocyst; **amylase >1000** in fluid. **Tx:** thoracentesis/drainage + conservative care (NPO, TPN, octreotide). Most close without surgery.

### Chronic Pancreatitis
- **Etiologies:** alcohol (MCC), idiopathic, biliary disease, autoimmune; genetic (PRSS1 in young). ↑ risk pancreatic CA.  
- **Symptoms:** chronic pain → back, weight loss; **exocrine** malabsorption/steatorrhea; **endocrine** DM.  
- **Dx:** CT—atrophy, calcifications, ductal dilation (“chain of lakes”); US (duct >4 mm, cysts, atrophy); ERCP/MRCP detail anatomy.  
- **Medical:** pain control, **pancreatic enzymes**, nutrition; celiac block PRN.  
- **Surgery—match morphology:**  
  - **Dilated duct ≥6 mm, head normal:** **Puestow** (longitudinal pancreaticojejunostomy).  
  - **Head-dominant disease (± duct dilation):** **Frey** (LPJ + limited head “coring”).  
  - **Duodenum-preserving head resection:** **Beger** (end-to-end or side-to-side PJ).  
  - **Distal duct stricture with normal head:** **Distal pancreatectomy** (consider spleen-preserving).  
  - **Minimal-change disease:** **bilateral thoracoscopic splanchnicectomy** for pain; resection/drainage ineffective.  
- **Complications to know:** CBD stricture → **hepaticojejunostomy** or **choledochojejunostomy** (exclude malignancy first). **Splenic vein thrombosis** → isolated gastric varices (bleeding) → **splenectomy**.

### Hereditary Pancreatitis & Insufficiency
- **Hereditary pancreatitis:** unexplained recurrent pancreatitis <35 y → consider **PRSS1** testing; ↑ lifetime pancreatic CA risk.  
- **Exocrine insufficiency:** steatorrhea, weight loss; **fecal fat** testing. **Tx:** high-carb/high-protein, **low-fat** diet + **pancreatic enzymes**. Endocrine function often preserved until late.

### Cystic Neoplasms
- **Serous cystadenoma:** very low malignant risk; microcystic, central scar; **low CEA**; resect if symptomatic/growing.  
- **Mucinous cystic neoplasm (MCN):** thick-walled, septated, **ovarian-type stroma**, body/tail; **high CEA**; **resect all fit patients**.  
- **IPMN:** main-duct, branch-duct, or mixed; mucin at **fish-mouth papilla** pathognomonic for main-duct.  
- **Cyst fluid:** **CEA >192** → mucinous; **high amylase** → duct communication (pseudocyst/IPMN).

**IPMN – Fukuoka-Guided Management**  
{:.qr-note}

| Category | Criteria | Action |
|---|---|---|
| **High-risk stigmata** | Obstructive jaundice; enhancing solid component/mural nodule ≥5 mm; **main duct ≥10 mm** | **Resect** (if fit) |
| **Worrisome features** | Cyst **>3 cm**; thickened/enhancing wall; non-enhancing mural nodule; lymphadenopathy; **MPD 5–9 mm**; abrupt MPD change with distal atrophy; rapid growth; pancreatitis | **EUS** ± FNA → **Resect** if concerning EUS/cytology or patient/size risk (e.g., young with >2 cm) |
| **Low-risk BD-IPMN** | None of the above | **Surveillance** (interval by size/center protocol) |
{:.qr-table}

*Age heuristic:* **Daughter = solid pseudopapillary**, **Mother = mucinous**, **Grandmother = serous**.

### Pancreatic Neuroendocrine Tumors (PNETs)
- **Epidemiology:** 1–2% of pancreatic tumors; **nonfunctional** common (60–90% malignant; often late presentation).  
- **Localization:** multiphase CT/MRI → **EUS**; somatostatin receptor imaging for most (not great for insulinoma); selective arterial testing if needed.  
- **Principles:** resect locoregional disease; **enucleate** small benign-appearing tumors away from duct; formal resection for malignant/high-risk; **cholecystectomy** if long-term somatostatin analogs anticipated.

**Functional PNET Snapshot**  
{:.qr-note}

| Tumor | Key features | Labs/Tests | Typical location | Operation |
|---|---|---|---|---|
| **Insulinoma** (MC functional) | Whipple triad (fasting hypoglycemia, neuroglycopenia, relief w/ glucose); 90% benign | 72-h fast: glucose <55 with **↑ insulin, C-peptide, proinsulin**, low β-hydroxybutyrate; ↑ glucose after glucagon | Throughout pancreas | Enucleation if small/benign; formal resection if malignant |
| **Gastrinoma** | Refractory PUD ± diarrhea/weight loss; **gastrin >1000** with low pH; **secretin test ↑ >200** | FSG, secretin test; SSTR imaging/EUS | **Gastrinoma triangle** (cystic–CBD junction; 2nd–3rd duodenum; neck–body pancreas) | Enucleation if small noninvasive; **Whipple** if large/invasive; node dissection |
| **Glucagonoma** | 4 D’s: **dermatitis (necrolytic migratory erythema)**, DM, depression, DVT | Fasting glucagon 1000–5000 | **Tail** | **Distal pancreatectomy** + nodes |
| **Somatostatinoma** | Cholecystitis, DM, steatorrhea; often malignant | SSTR imaging | **Head/duodenum** | Formal resection + nodes; **cholecystectomy** |
| **VIPoma** | **WDHA** (watery diarrhea, hypokalemia, achlorhydria) | ↑ VIP during diarrhea | Body/tail; extra-pancreatic possible | Formal resection + nodes; **cholecystectomy** |
{:.qr-table}

### Pancreatic Adenocarcinoma
- **Risk factors:** smoking, heavy alcohol, chronic pancreatitis, ↑BMI, long-standing DM; common mutations **KRAS, TP53, CDKN2A, SMAD4**. **CA 19-9** most useful marker (not screening).  
- **Imaging/staging:** pancreatic-protocol CT; **EUS** for nodes/vessels; PET/CT selectively for suspected mets; **staging laparoscopy** in high-risk (borderline-resectable, high CA19-9, large primary, suspicious nodes).  
- **Biopsy:** **not required** before upfront resection; **required** before neoadjuvant therapy or for unresectable/metastatic disease.  
- **Preop biliary drainage:** no survival benefit; ↑ wound infections. For upfront surgery, drain **only** for severe pruritus, cholangitis, or coagulopathy. If neoadjuvant planned and jaundiced → drain. **Self-expanding metal stents** preferred (patency, easy placement).  
- **Venous resection:** PV/SMV resection/reconstruction acceptable to achieve **R0** if reconstructible.  
- **Adjuvant therapy:** **everyone** after R0/R1 (e.g., modified FOLFIRINOX).  
- **Borderline-resectable:** consider **neoadjuvant chemo-RT** (tissue via EUS-FNA first).

**Resectability Criteria (CT-based)**  
{:.qr-note}

| Category | Arterial | Venous (PV/SMV) | Distant disease |
|---|---|---|---|
| **Resectable** | **No** arterial tumor contact | ≤180° contact **without** contour irregularity | **Absent** |
| **Borderline-resectable** | Contact **<180°** with **SMA or celiac**; or **common hepatic** contact permitting safe resection/recon | Involvement **amenable** to resection/recon; short-segment occlusion allowed if reconstructible | **Absent** |
| **Unresectable** | **>180°** contact with **SMA/celiac** or unreconstructable arterial involvement | **Unreconstructable** PV/SMV involvement | **Present** (or peritoneal/liver mets) |
{:.qr-table}

</details>

---

<details markdown="1">
<summary><strong>Pancreas Q&amp;A Review (condensed)</strong></summary>

- Two most common causes of acute pancreatitis? **Alcohol, gallstones.**  
- Antibiotics in pancreatitis? **No** (unless **infected necrosis**). **Imipenem** if infection suspected.  
- Gallstone pancreatitis timing? **Clear duct** if obstruction/cholangitis; **cholecystectomy same admission** when improved.  
- Atlanta terms <4 vs ≥4 weeks? **APFC/ANC** → **pseudocyst/WON**.  
- Infected necrosis management? **Step-up** (drain → VARD/endoscopic → open last).  
- Chronic pancreatitis with dilated duct ≥6 mm? **Puestow**. Head-dominant? **Frey**. Distal stricture, normal head? **Distal pancreatectomy**. Minimal-change? **Splanchnicectomy**.  
- Pseudocyst algorithm? **Image duct first** (ERCP/MRCP) → observe ≥6 wk unless symptoms/infection/>6 cm → endoscopic or surgical drainage.  
- Cyst fluid **CEA >192** suggests? **Mucinous** (MCN/IPMN). High **amylase**? **Duct communication**.  
- IPMN high-risk stigmata? **Obstructive jaundice, mural nodule ≥5 mm, main duct ≥10 mm** → **resect**.  
- Insulinoma workup hallmark? 72-h fast: low glucose with **↑ insulin/C-peptide/proinsulin**, low β-hydroxybutyrate; **glucagon raises glucose**.  
- Gastrinoma test? **Secretin paradox** (↑ gastrin >200). Triangle borders? **Cystic–CBD junction; 2nd–3rd duodenum; neck–body pancreas.**  
- VIPoma syndrome? **WDHA.** Glucagonoma rash? **Necrolytic migratory erythema.**  
- Preop stent for pancreatic CA? Only for **pruritus, cholangitis, coagulopathy** (or neoadjuvant if jaundiced). **Metal** stents preferred.  
- Arterial rule of resectability? **>180° SMA/celiac** contact = **unresectable**.

</details>

---

## Figures

![Figure placeholder 1](./images/11_09-pancreas_pXX_i1.png)
![Figure placeholder 2](./images/11_09-pancreas_pXX_i2.png)
![Figure placeholder 3](./images/11_09-pancreas_pXX_i3.png)
